Merck announced today that the European Commission (EC) has approved two new indications for Keytruda in the treatment of gastrointestinal cancers.

The first concerns the combination of Keytruda with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of locally advanced, unresectable or metastatic negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.

The second concerns Keytruda administered with gemcitabine and cisplatin as first-line treatment for unresectable or metastatic locally advanced biliary tract carcinoma (BTC) in adults.

These EC approvals follow positive recommendations from the Committee for Medicinal Products for Human Use received in October and November 2023, with in each indication respective 22% and 17% reductions in the risk of death compared with chemotherapy alone.

Copyright (c) 2023 CercleFinance.com. All rights reserved.